Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 1
2013 2
2014 2
2017 1
2018 1
2020 1
2021 3
2022 1
2023 3
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.
van den Bent MJ, Tesileanu CMS, Wick W, Sanson M, Brandes AA, Clement PM, Erridge S, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Caparrotti F, Lesimple T, Clenton S, Gijtenbeek A, Lim E, Herrlinger U, Hau P, Dhermain F, de Heer I, Aldape K, Jenkins RB, Dubbink HJ, Kros JM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, French P, Baumert BG. van den Bent MJ, et al. Among authors: gijtenbeek a. Lancet Oncol. 2021 Jun;22(6):813-823. doi: 10.1016/S1470-2045(21)00090-5. Epub 2021 May 14. Lancet Oncol. 2021. PMID: 34000245 Free PMC article. Clinical Trial.
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.
van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, Wick W, Kros JM. van den Bent MJ, et al. Among authors: gijtenbeek a. Lancet. 2017 Oct 7;390(10103):1645-1653. doi: 10.1016/S0140-6736(17)31442-3. Epub 2017 Aug 8. Lancet. 2017. PMID: 28801186 Free PMC article.
A bilateral foot drop due to neuroschistosomiasis.
Wilbers J, Idema A, Gijtenbeek A. Wilbers J, et al. Among authors: gijtenbeek a. J Neurol. 2010 May;257(5):853-5. doi: 10.1007/s00415-010-5464-0. Epub 2010 Feb 3. J Neurol. 2010. PMID: 20127348
Glioma patient-reported outcomes: patients and clinicians.
Peeters M, Ottenheijm G, Bienfait P, Eekers D, Gijtenbeek A, Hanse M, Koekkoek J, van Leeuwen L, Tijssen C, Dirven L, Taphoorn M. Peeters M, et al. Among authors: gijtenbeek a. BMJ Support Palliat Care. 2023 Oct;13(e1):e205-e212. doi: 10.1136/bmjspcare-2020-002699. Epub 2021 Mar 2. BMJ Support Palliat Care. 2023. PMID: 33653735
Head-To-Head Comparison of PET and Perfusion Weighted MRI Techniques to Distinguish Treatment Related Abnormalities from Tumor Progression in Glioma.
Henssen D, Leijten L, Meijer FJA, van der Kolk A, Arens AIJ, Ter Laan M, Smeenk RJ, Gijtenbeek A, van de Giessen EM, Tolboom N, Oprea-Lager DE, Smits M, Nagarajah J. Henssen D, et al. Among authors: gijtenbeek a. Cancers (Basel). 2023 May 5;15(9):2631. doi: 10.3390/cancers15092631. Cancers (Basel). 2023. PMID: 37174097 Free PMC article. Review.
Rare Primary Central Nervous System Tumors in Adults: An Overview.
Franceschi E, Frappaz D, Rudà R, Hau P, Preusser M, Houillier C, Lombardi G, Asioli S, Dehais C, Bielle F, Di Nunno V, van den Bent M, Brandes AA, Idbaih A; EURACAN Domain 10. Franceschi E, et al. Front Oncol. 2020 Jun 26;10:996. doi: 10.3389/fonc.2020.00996. eCollection 2020. Front Oncol. 2020. PMID: 32676456 Free PMC article. Review.
Apparent Diffusion Coefficient Metrics to Differentiate between Treatment-Related Abnormalities and Tumor Progression in Post-Treatment Glioblastoma Patients: A Retrospective Study.
van den Elshout R, Herings SDA, Mannil M, Gijtenbeek AMM, Ter Laan M, Smeenk RJ, Meijer FJA, Scheenen TWJ, Henssen DJHA. van den Elshout R, et al. Among authors: gijtenbeek amm. Cancers (Basel). 2023 Oct 14;15(20):4990. doi: 10.3390/cancers15204990. Cancers (Basel). 2023. PMID: 37894355 Free PMC article.
Rare central nervous system tumors in adults: a population-based study of ependymomas, pilocytic astrocytomas, medulloblastomas, and intracranial germ cell tumors.
Ho VKY, Gijtenbeek AJMM, Wagemakers M, Taal W, van Linde ME, Swaak-Kragten AT, Kurt E, van der Weide HL, Wesseling P, de Vos FY, Bromberg JEC. Ho VKY, et al. Among authors: gijtenbeek ajmm. Neurooncol Adv. 2022 Apr 22;4(1):vdac062. doi: 10.1093/noajnl/vdac062. eCollection 2022 Jan-Dec. Neurooncol Adv. 2022. PMID: 35664556 Free PMC article.
Spatial and temporal evolution of distal 10q deletion, a prognostically unfavorable event in diffuse low-grade gliomas.
van Thuijl HF, Scheinin I, Sie D, Alentorn A, van Essen HF, Cordes M, Fleischeuer R, Gijtenbeek AM, Beute G, van den Brink WA, Meijer GA, Havenith M, Idbaih A, Hoang-Xuan K, Mokhtari K, Verhaak RG, van der Valk P, van de Wiel MA, Heimans JJ, Aronica E, Reijneveld JC, Wesseling P, Ylstra B. van Thuijl HF, et al. Among authors: gijtenbeek am. Genome Biol. 2014 Sep 23;15(9):471. doi: 10.1186/s13059-014-0471-6. Genome Biol. 2014. PMID: 25245118 Free PMC article.
16 results